DIABIO.ST

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

DCF fair valuemodel estimate

Intrinsic value

$0.05

Price

$0.01

Implied upside

+236%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
DIABIO.STDiagonal Bio AB (publ)	$0.01	+0.00%	$20M	—
AEGIR.STAegirBio AB (publ)	$0.43	+3.88%	$15M	—
AMNI.STAmniotics AB (publ)	$0.01	+5.88%	$15M	—
CYXO.STCyxone AB (publ)	$0.02	+0.00%	$7M	—
IDOGEN.STIdogen AB (publ)	$0.12	-2.82%	$13M	—
L2S.STLearning 2 Sleep L2S AB (publ)	$0.02	+2.50%	$12M	—
PHARM.STPharmiva AB (publ)	$0.56	-16.17%	$13M	—

Source: Financial Modeling Prep · peers by sector/industry

Diagonal Bio AB (publ)

Diagonal Bio AB is a Swedish biotechnology firm dedicated to advancing the Panviral platform. This innovative technology is engineered to pinpoint and diagnose minute genetic fragments belonging to a range of pathogens, such as viruses, bacteria, and fungi. Established in 2020, the company's main operations are based in Lund, Sweden.

diagonalbio.com

Employees: 4
IPO / List date: Jul 16, 2021
HQ: SE

Held by traders on TradeandTell

No one on the platform currently holds DIABIO.ST.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in DIABIO.ST as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded DIABIO.ST yet.